PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King , President of DSM Biologics, the biopharmaceutical manufacturing business of DSM Pharmaceutical Products, stated, "We are thrilled to announce the June opening of our new cGMP facility in Brisbane. This operation combines DSM's twenty five years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility. Our partnership with the Government of Queensland and the Commonwealth of Australia has led to this important addition to the Australian biotechnology industry and will be a key contributor to the entire Asia-Pacific region."
Alexander Wessels , President and CEO of DSM Pharmaceutical Products commented, "We are particularly delighted to be bringing our world-class operating ability to the Asia-Pacific region, an important growth area in our strategic development in the biopharmaceutical field; to provide further value to our customers in this region and around the globe." Australia has a vibrant biotechnology industry, but previously had no custom mammalian-based biopharmaceutical manufacturing operation in country. The Queensland Government formed BioPharmaceuticals Australia (BPA), who has partnered with DSM to bring this new facility and operation to Brisbane.
David Hughes , CEO of BioPharmaceuticals Australia said, "The opening
|SOURCE DSM Pharmaceutical Products|
Copyright©2012 PR Newswire.
All rights reserved